Histogen Inc.
US ˙ OTCPK ˙ US43358Y2028

Introduction

This page provides a comprehensive analysis of the known insider trading history of Paul H Klingenstein. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Paul H Klingenstein has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:CLVS / Clovis Oncology Inc Director 42,223
US:032420AC5 / Anacor Pharmaceuticals Inc. Bond 2.0% 15 OCT 2021 Director 15,000
US:CNAT / Conatus Pharmaceuticals Inc. Director 8,731
US:ETRM / EnteroMedics Inc Director 10,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Paul H Klingenstein. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases HSTOQ / Histogen Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in HSTOQ / Histogen Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

HSTOQ / Histogen Inc. Insider Trades
Insider Sales HSTOQ / Histogen Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in HSTOQ / Histogen Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

HSTOQ / Histogen Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Paul H Klingenstein as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2021-06-11 2021-06-10 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 42,223 42,223
2020-06-05 2020-06-04 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 40,138 40,138
2019-07-31 2019-07-29 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
M - Exercise -25,862 0 -100.00
2019-07-31 2019-07-29 4 CLVS Clovis Oncology, Inc.
Common Stock
M - Exercise 25,862 59,327 77.28 0.29 7,500 17,205
2019-06-07 2019-06-06 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 28,882 28,882
2018-10-15 2018-10-11 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 14,770 14,770
2017-06-08 2017-06-08 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 10,000 10,000
2016-06-10 2016-06-09 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 10,000 10,000
2015-06-15 2015-06-11 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 10,000 10,000
2014-06-16 2014-06-12 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 12,414 12,414
2014-05-30 2014-05-29 4 ANAC Anacor Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 15,000 15,000
2014-02-25 2014-02-19 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
J - Other 8,731 8,731
2014-02-25 2014-02-19 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
J - Other 20,322 20,322
2014-02-25 2014-02-19 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
J - Other -36,634 0 -100.00
2014-02-25 2014-02-19 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
J - Other 36,634 36,634
2014-02-25 2014-02-19 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
J - Other -30,216 22,203 -57.64
2014-02-25 2014-02-19 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
J - Other -1,283,589 943,355 -57.64
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Stock Option (right to buy)
A - Award 30,000 30,000
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Warrant to Purchase Common Stock
C - Conversion 120 120
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Warrant to Purchase Series B Preferred Stock
C - Conversion -997 0 -100.00
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Warrant to Purchase Common Stock
X - Other -1,727 0 -100.00
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Warrant to Purchase Common Stock
C - Conversion 1,727 1,727
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Warrant to Purchase Series A Preferred Stock
C - Conversion -5,701 0 -100.00
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Warrant to Purchase Series A Preferred Stock
C - Conversion -8,552 0 -100.00
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Series B Preferred Stock
C - Conversion -137,626 0 -100.00
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Series A Preferred Stock
C - Conversion -246,775 0 -100.00
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Warrant to Purchase Common Stock
C - Conversion 5,131 5,131
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Warrant to Purchase Common Stock
C - Conversion -42,336 0 -100.00
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Warrant to Purchase Common Stock
X - Other -73,395 0 -100.00
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Warrant to Purchase Common Stock
C - Conversion 73,395 73,395
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Warrant to Purchase Series A Preferred Stock
C - Conversion -242,205 0 -100.00
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Warrant to Purchase Series A Preferred Stock
C - Conversion -363,308 0 -100.00
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Series B Preferred Stock
C - Conversion -5,846,236 0 -100.00
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Series A Preferred Stock
C - Conversion -10,483,166 0 -100.00
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
P - Purchase 2,470 52,419 4.95 11.00 27,170 576,609
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
J - Other 251 49,949 0.51 11.00 2,761 549,439
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
S - Sale -14 49,698 -0.03 11.00 -154 546,678
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
X - Other 1,727 49,712 3.60 0.08 142 4,101
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
C - Conversion 46,594 47,985 3,349.68
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
P - Purchase 104,952 2,226,944 4.95 11.00 1,154,472 24,496,384
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
J - Other 10,614 2,121,992 0.50 11.00 116,754 23,341,912
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
S - Sale -552 2,111,378 -0.03 11.00 -6,072 23,225,158
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
X - Other 73,395 2,111,930 3.60 0.08 6,055 174,234
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
C - Conversion 1,979,321 2,038,535 3,342.66
2013-07-24 3 CNAT Conatus Pharmaceuticals Inc
Common Stock
59,214
2013-07-24 3 CNAT Conatus Pharmaceuticals Inc
Common Stock
1,391
2013-06-17 2013-06-13 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 12,414 12,414
2013-06-07 2013-06-06 4 ANAC Anacor Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 15,000 15,000
2013-05-10 2013-05-08 4 ETRM EnteroMedics Inc
Stock Option (right to buy)
A - Award 10,000 10,000
2012-06-18 2012-06-14 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 12,414 12,414
2012-06-01 2012-05-30 4 ANAC Anacor Pharmaceuticals Inc
Stock Option (right to buy)
A - Award 12,500 12,500
2012-05-11 2012-05-09 4 ETRM EnteroMedics Inc
Stock Option (right to buy)
A - Award 10,000 10,000
2012-03-22 2011-11-21 4 CLVS Clovis Oncology, Inc.
Series A-1 Preferred Stock
C - Conversion -507,119 0 -100.00
2012-03-22 2011-11-21 4 CLVS Clovis Oncology, Inc.
5% Convertible Note due 2012
C - Conversion 0
2012-03-22 2011-11-21 4 CLVS Clovis Oncology, Inc.
5% Convertible Note due 2012
C - Conversion 0
2012-03-22 2011-11-21 4 CLVS Clovis Oncology, Inc.
Series B Preferred Stock
C - Conversion -21,909 0 -100.00
2012-03-22 2011-11-21 4 CLVS Clovis Oncology, Inc.
Series B Preferred Stock
C - Conversion -1,097,661 0 -100.00
2012-03-22 2011-11-21 4 CLVS Clovis Oncology, Inc.
Series A-1 Preferred Stock
C - Conversion -10,122 0 -100.00
2012-03-22 2011-11-21 4 CLVS Clovis Oncology, Inc.
Series A-2 Preferred Stock
C - Conversion -10,122 0 -100.00
2012-03-22 2011-11-21 4 CLVS Clovis Oncology, Inc.
Series A-2 Preferred Stock
C - Conversion -507,119 0 -100.00
2012-03-22 2011-11-21 4 CLVS Clovis Oncology, Inc.
Common Stock
P - Purchase 7,813 25,509 44.15 13.00 101,569 331,617
2012-03-22 2011-11-21 4 CLVS Clovis Oncology, Inc.
Common Stock
P - Purchase 391,478 1,278,156 44.15 13.00 5,089,214 16,616,028
2012-03-22 2011-11-21 4 CLVS Clovis Oncology, Inc.
Common Stock
C - Conversion 3,162 17,696 21.76
2012-03-22 2011-11-21 4 CLVS Clovis Oncology, Inc.
Common Stock
C - Conversion 158,439 886,678 21.76
2012-03-22 2011-11-21 4 CLVS Clovis Oncology, Inc.
Common Stock
C - Conversion 14,534 14,534
2012-03-22 2011-11-21 4 CLVS Clovis Oncology, Inc.
Common Stock
C - Conversion 728,239 728,239
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)